TL;DR
Turn your wind-down time into listening time
- Thousands of audiobooks, podcasts and originals
- Listen on your phone, tablet or Echo — also offline
- Cancel anytime
The Buck Institute and Georgetown University are co-leading SEEDS, a four-year research effort backed by an ARPA-H award of up to $51.7 million. The consortium will combine AI-based predictions and experiments to study how intrinsically disordered proteins change under different cellular conditions, initially focusing on Alzheimer’s disease and Ewing sarcoma. The project aims to inform future diagnostics and treatments, but those outcomes are not yet established.
The Buck Institute for Research on Aging and Georgetown University are co-leading a four-year consortium that has received an Advanced Research Projects Agency for Health award of up to $51.7 million to study how disease-linked proteins change shape before lasting cellular damage. The project, called SEEDS, will initially investigate Alzheimer’s disease and Ewing sarcoma, combining computational predictions with laboratory experiments.
SEEDS stands for Sequence-to-disease: Environment-aware Ensembles of Disordered proteins at Scale. Its researchers aim to predict how a protein’s sequence and its surroundings inside a cell influence the shapes it takes and whether those forms shift toward disease-associated behavior. The group plans to use the resulting knowledge to support future approaches to detecting, slowing or treating disease; the award announcement does not report a diagnostic or treatment already developed.
The work centers on intrinsically disordered proteins, which do not settle into one stable three-dimensional structure. Their behavior can change with cellular conditions such as acidity, molecular crowding, metals, metabolites and chemical modifications. The consortium will study these influences through physics-guided artificial intelligence and experimental measurements, using experiments to test and refine computational predictions rather than relying on models alone.
The consortium is co-led by Priyanka Joshi of Georgetown and Chuankai (Kai) Zhou of the Buck Institute. It includes researchers from nine academic institutions and seven industry partners. The source report identifies Alzheimer’s disease and Ewing sarcoma as the initial areas of focus; it does not specify individual protein targets, a public project schedule or how much of the maximum award will ultimately be paid.
Why Early Protein Shifts Matter
Protein misfolding and aggregation are associated with Alzheimer’s disease, ALS, some cancers and other chronic or degenerative conditions. The project focuses on a research gap: scientists can capture observations of some proteins, often after they have clumped, but cannot reliably predict from those snapshots how the proteins behave as cellular conditions change or when a harmful shift begins.
Many of these proteins are described as difficult to target with conventional drugs because they lack the stable shapes and binding pockets that many drug-development approaches are designed around. A way to predict their behavior could help researchers identify possible points for detection or intervention earlier in the disease process. That is the project’s rationale, not evidence that early detection or an effective intervention will result.
Pairing models with experiments may also help researchers check whether a predicted pattern holds under different conditions. If the approach produces reliable, reusable findings, it could give scientists a way to move beyond examining disordered proteins one at a time. The award announcement, however, provides no results yet on prediction accuracy, clinical usefulness or patient benefit.
AI-based protein structure prediction tools
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
The BIOGAMI Research Program
SEEDS is part of ARPA-H’s BIOmolecular Grammar for protein Aggregation Modulation and Intervention program, known as BIOGAMI. The program focuses on early stages of protein dysfunction, before misfolding or aggregation may contribute to lasting damage. Its “molecular grammar” concept refers to finding rules that link a protein’s sequence and environment with its behavior.
AI tools such as AlphaFold have advanced protein research by using large bodies of structural data. But the source report says there is less comparable structural information for intrinsically disordered proteins, making them harder to model. SEEDS aims to build knowledge about these proteins at scale while investigating selected cases in detail. It combines Georgetown’s INTREPID and the Buck Institute’s SHIFT research teams, according to the report.
“We aim to uncover the principles that determine when these proteins remain in healthy functional ensembles and when they begin to shift toward disease-associated states.”
— Chuankai (Kai) Zhou, assistant professor at the Buck Institute
As an affiliate, we earn on qualifying purchases.
Questions the Project Must Answer
The announcement does not say which specific proteins the team will study first, how it will define or measure an early harmful shift, or what milestones will mark progress over the four-year award. It also does not report that the models can already predict disease-related changes reliably.
It remains unclear whether findings will lead to practical diagnostic tests or treatments, and how long that translation might take. The award is described as worth up to $51.7 million; the source does not state the amount already disbursed or the conditions governing the final total. These are research aims, not confirmed clinical outcomes.
As an affiliate, we earn on qualifying purchases.
Four Years of Model Testing
Over the planned four-year effort, the team intends to develop models linking protein sequence and cellular environment to protein behavior, then compare their predictions with experiments under varied conditions. Those tests are expected to help researchers revise and evaluate the models. The source report gives no dated interim results, recruitment plans or specific public deliverables.
The next substantive update will need to show what proteins and conditions the consortium has examined, whether predictions match experimental measurements, and whether the results identify changes that can be detected or redirected. Until such evidence is reported, the potential for new diagnostics and treatments remains a goal of the project.
early Alzheimer's disease diagnostic tests
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Key Questions
What is the SEEDS project?
SEEDS is a four-year consortium led by the Buck Institute and Georgetown University to study how intrinsically disordered proteins behave as their cellular environment changes. It will combine computational modeling and experiments.
How much funding did the consortium receive?
ARPA-H awarded the effort up to $51.7 million. The source report does not say how much has been disbursed or whether the consortium will receive the full maximum amount.
Which diseases will the team study first?
The project has an initial focus on Alzheimer’s disease and Ewing sarcoma. The announcement does not list specific protein targets within those diseases.
Does the award mean a new treatment is available?
No. The award funds research into protein behavior. Diagnostics and treatments are possible longer-term aims; no new test or therapy is reported as developed or available.
Why are these proteins difficult to study?
Intrinsically disordered proteins can take many shapes rather than adopting one stable structure. Their behavior can depend on cellular conditions, and the source report says researchers have less structural data for them than for many proteins used to train existing AI tools.
Source: rss
Fall Picks
fall essentials
As an affiliate, we earn on qualifying purchases.
